Vitamin E Intake and Risk of Amyotrophic Lateral Sclerosis: A Pooled Analysis of Data From 5 Prospective Cohort Studies

Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
American journal of epidemiology (Impact Factor: 5.23). 02/2011; 173(6):595-602. DOI: 10.1093/aje/kwq416
Source: PubMed


The authors investigated whether vitamin E intake was associated with amyotrophic lateral sclerosis (ALS) in the Nurses' Health Study (1976-2004), the Health Professionals Follow-up Study (1986-2004), the Cancer Prevention Study II Nutrition Cohort (1992-2004), the Multiethnic Cohort Study (1993-2005), and the National Institutes of Health-AARP Diet and Health Study (1995-2005). ALS deaths were identified through the National Death Index. In the Nurses' Health Study and the Health Professionals Follow-up Study, confirmed nonfatal ALS cases were also included. Cohort-specific results were estimated using Cox proportional hazards models and pooled using random-effects models. Among 1,055,546 participants, 805 developed ALS. Overall, using vitamin E supplements was not associated with ALS. However, within cohorts with information on duration of vitamin E supplement use (231 cases), ALS rates declined with increasing years of use (P-trend=0.01). Compared with nonusers, the multivariable-adjusted relative risk was 1.05 (95% confidence interval (CI): 0.60, 1.84) among users for ≤1 year (12 cases), 0.77 (95% CI: 0.33, 1.77) among users for 2-4 years (7 cases), and 0.64 (95% CI: 0.39, 1.04) among users for ≥5 years (18 cases). For dietary vitamin E intake, the multivariable-adjusted relative risk comparing the highest quartile with the lowest was 0.79 (95% CI: 0.61, 1.03); an inverse dose-response was evident in women (P-trend=0.002) but not in men (P-trend=0.71). In this large, pooled prospective study, long-term vitamin E supplement use was associated with lower ALS rates. A possible protective effect of vitamin E deserves further consideration.

Download full-text


Available from: Giancarlo Logroscino
    • "Age is also another important risk factor but, contrary to other disorders in which aging is the major risk factor, the incidence of ALS declines at the age of 75 years (Al-Chalabi and Hardiman, 2013), so it does not have the same influence as in Alzheimer's disease and Parkinson's disease. On the other hand, the influence of some protective factors, e.g., cardiovascular risk factors (Körner et al., 2013), dietary supplements of vitamin D (Camu et al., 2014), vitamin E (Wang et al., 2011), or magnesium (Fondell et al., 2013), longer reproductive lifespan or prolonged estrogen exposure (de Jong et al., 2013), and treatment with non-steroidal anti-inflammatory drugs (Popat et al., 2007), has been also investigated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cannabinoids form a singular family of plant-derived compounds (phytocannabinoids), endogenous signaling lipids (endocannabinoids), and synthetic derivatives with multiple biological effects and therapeutic applications in the CNS and also in the periphery. One of these properties is the improvement of neuronal homeostasis and survival, which is exerted by the combination of beneficial effects on multiple targeted cytotoxic mechanisms. This potential is promising for acute and chronic neurodegenerative disorders, which are lacking at present of efficacious disease-modifying therapies. In this chapter, we review the experimental evidence supporting that different cannabinoid compounds may be neuroprotective in amyotrophic lateral sclerosis (ALS), a devastating chronic progressive neurodegenerative disorder affecting upper and/or lower motor neurons, which results in muscle denervation, atrophy, and paralysis. This experimental evidence supports a prompt and promising clinical exploitation of cannabinoid-based medicines for ALS and other motor neuron disorders.
    No preview · Chapter · Dec 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis is a rare neurodegenerative disease. It is characterized by motoneurons progressive degeneration. Associated with a paralysis of the legs, arms and the respiratory muscles, its evolution is lethal. Riluzole is the only drug available with an marketing authorisation (autorisation de mise sur le marché [AMM]) in this indication. In the beginning stages of the disease it demonstrated a modest efficacy by prolonging survival for a few months. Although the physiopathological mechanisms of this disease have not been totally solved, the progression of knowledge in recent years in this area led to the development of a large number of neuroprotective agents which showed effective results in animal models of ALS and which could be good candidates for the treatment of ALS. Several clinical trials have been conducted about antiglutamatergic, antioxidant, antiapoptotic agents and growing cell factors but they failed to demonstrate efficacy on survival or quality of life. Therefore, clinical trials using innovative therapeutics and stem cells are ongoing and offer more distant hope.
    No preview · Article · Mar 2013 · Thérapie
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron death, leading to muscle atrophy, paralysis, and death usually within 3 to 5 years after diagnosis. Most cases are sporadic, with still undefined etiopathogenesis. Both the innate and adaptive immune systems are involved in ALS, with special participation of T lymphocytes and microglia. Inflammation plays a dual role in the disease, protective and T regulatory cell rich in the early stages and deleterious as disease progresses. Attempts to modulate immune/inflammatory system response are reported in the literature, and while beneficial effects are achieved in ALS animal models, results of most clinical trials have been disappointing. The impaired blood–brain barrier is an important feature in the pathogenesis of ALS and likely affects the immune system response. The present review describes the role of the immune system in ALS pathogenesis and the tight coupling of immunity and central nervous system barrier function.
    No preview · Article · Sep 2012
Show more